Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients.

Melissa Corson, Ashley Moch, Sammy Saab

Open access · greenAbstract read

In one paragraph

Article in Gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

0.8field-weighted citation impact, top 26% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

[Sustained virologic response in patients with hepatitis C and chronic kidney disease].Revista medica del Instituto Mexicano del Seguro Social · 2022
Article
Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030.World journal of gastroenterology · 2022
Article
Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.Annals of gastroenterology · 2021
Article
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.Medicine · 2020
Observational
The Psychosocial Burden of HCV Infection and the Impact of Antiviral Therapy on the Quality of Life in Liver and Kidney Transplant Recipients: A Pilot Study.Gastroenterology research and practice · 2020
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Melissa CorsonDr Corson is a medical resident in the Department of Medicine at the University of California at Los Angeles in Los Angeles, California. Ms Moch is a research assistant in the Department of Surgery at the University of California at Los Angeles. Dr Saab is a professor in the Departments of Medicine and Surgery at the University of California at Los Angeles.

Ashley MochDr Corson is a medical resident in the Department of Medicine at the University of California at Los Angeles in Los Angeles, California. Ms Moch is a research assistant in the Department of Surgery at the University of California at Los Angeles. Dr Saab is a professor in the Departments of Medicine and Surgery at the University of California at Los Angeles.

Sammy SaabDr Corson is a medical resident in the Department of Medicine at the University of California at Los Angeles in Los Angeles, California. Ms Moch is a research assistant in the Department of Surgery at the University of California at Los Angeles. Dr Saab is a professor in the Departments of Medicine and Surgery at the University of California at Los Angeles.

Los Angeles Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An important interplay exists between hepatitis C virus (HCV) infection and chronic kidney disease (CKD). HCV infection is associated with an increased risk of morbidity and mortality in patients coinfected with CKD, and patients with CKD have an increased risk of HCV infection. Direct-acting antiviral (DAA) agents have changed the landscape of treatment with excellent sustained virologic response rates and fewer side effects than previously seen. An increasing number of studies demonstrate that DAA agents are efficacious and safe both in patients on dialysis and in patients who have undergone kidney transplantation. This article reviews the current literature on approved DAA agents for the treatment of HCV infection in patients on dialysis and in kidney transplant recipients.

Indexed as

chronic kidney diseasedirect-acting antiviral agentsHepatitis C viruskidney transplant

Identifiers

PMID29991935

PMCPMC6034610

OpenAlexW2997791083

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.